Fig. 2
From: Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy
Balixafortide improves anti-PD-1 immunotherapy to reduce tumor growth in mice with TNBC. (A) We implanted mice with E0771 breast cancer cells and randomly assigned mice to listed treatment groups on day 2. Groups 1 and 3 received 4 doses of anti-PD-1 antibody at 5 mg/kg per dose every 3 days for 4 cycles. Groups 1 and 2 received 20 mg/kg balixafortide through subcutaneous injection in the rear flank daily. Control mice received matched vehicles only (n = 10 /group). (B) We calculated tumor volumes by caliper measurements. To account for differences in days required to reach pre-defined study endpoints, we normalized the reported duration of each experiment to fraction experiment progression. Presented data are mean values + SEM combined from 2 different experiments. We compared differences across groups at each time point by ANOVA corrected for multiple comparisons. *, p < 0.05; **, p < 0.01. (C) Graph shows overall survival of mice in different treatment groups with log-rank p-values calculated using a Mantel-Cox test. Asterisks in legend symbolize significance (* <0.05; ** <0.01). We normalized data to fraction of days to reach the study endpoint (defined as 1.0), combining two different experiments with different overall days until endpoint.
